ICAM1 and rheumatoid arthritis: These phenotypes, or similar patterns according to a recently revised classification (97), have been shown to present measurable associations with specific biomarkers in peripheral blood (CXCL13 and soluble ICAM-1 for the lymphoid and myeloid phenotype, respectively) and to be detectable in early-untreated RA, strengthening their differential biologic impact also at systemic level and in the absence of treatment biases (95, 97).